Rochester, Minnesota
Phase 1 cancer trials in Rochester, MN
68 Phase 1 cancer studies are recruiting participants at sites in Rochester as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Rochester at a glance
- 68 studies are recruiting at a site in Rochester.
- By phase: Early Phase 1 (2), Phase 1 (29), Phase 1/2 (37).
- By sponsor: industry (55), university, hospital or other (13).
- By research area: Breast Cancer (20), Lung Cancer (18), Lymphoma (17), Pancreatic Cancer (6), Prostate Cancer (6), Melanoma (1).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Rochester
Basic details from each study's public record (the 30 most recently updated of 68). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT06638307 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Mayo Clinic
- Registry record
- NCT05315700 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Mayo Clinic - Rochester
- Registry record
- NCT07213791 · updated
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Terremoto Biosciences Inc.
- Study site
- Mayo Rochester
- Registry record
- NCT07109726 · updated
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Mayo Clinic
- Registry record
- NCT06374459 · updated
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Cellectar Biosciences, Inc.
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07311993 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Lung cancer studies recruiting in Rochester
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07277413 · updated
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BlossomHill Therapeutics
- Study site
- Mayo Clinic Hospital - Rochester, MN
- Registry record
- NCT06706076 · updated
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- Mayo Clinic, Rochester
- Registry record
- NCT06720987 · updated
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Synthekine
- Study site
- Mayo Rochester
- Registry record
- NCT05098132 · updated
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06996782 · updated
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Mayo Clinic-Rochester /ID# 274512
- Registry record
- NCT06772623 · updated
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tango Therapeutics, Inc.
- Study site
- Mayo Clinic Cancer Center
- Registry record
- NCT06922591 · updated
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tango Therapeutics, Inc.
- Study site
- Mayo Clinic Cancer Center
- Registry record
- NCT06810544 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- Mayo Clinic Comprehensive Cancer Center
- Registry record
- NCT06026410 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Rochester
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Mayo Clinic
- Registry record
- NCT03972657 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- Mayo Clinic
- Registry record
- NCT05519449 · updated
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- K36 Therapeutics, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT07103018 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Melanoma studies recruiting in Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT05655312 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Lymphoma studies recruiting in Rochester
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04726241 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT05091424 · updated
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Mayo Clinic - Rochester
- Registry record
- NCT07101328 · updated
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Mayo Clinic - Rochester
- Registry record
- NCT07226843 · updated
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07123454 · updated
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Phase 1/2
- Ages 13 to 90
- All sexes
- Sponsor
- Vironexis Biotherapeutics Inc.
- Study site
- Mayo Clinic, Clinical Trials Referral Office
- Registry record
- NCT06533579 · updated
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Mayo Clinic in Rochester, Minnesota
- Registry record
- NCT06090539 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Rochester
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- RayzeBio, Inc.
- Registry record
- NCT07165132 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- Mayo Clinic in Rochester, Minnesota
- Registry record
- NCT06710756 · updated
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Study site
- Mayo Clinic
- Registry record
- NCT06973564 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- Mayo Clinic (Minnesota)
- Registry record
- NCT04657068 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Ask about studies near Rochester
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections